MicroRNA 4646 (miR-4646 (or MIR4646, hsa-miR-4646))

MicroRNA 4646 (miR-4646, or hsa-miR-4646) is a non-coding small RNA molecule classified as a microRNA, involved in post-transcriptional regulation of gene expression. It is characterized as a mirtronic miRNA, originating from the spliced intron of the ABHD16A gene. MiR-4646-5p acts as a tumor suppressor in triple negative breast cancer by reducing cell growth, proliferation, and migration, and inducing apoptosis in certain cellular contexts[1]. It exerts anti-angiogenic properties and modulates key pathways such as cholesterol biosynthesis and cytokine signaling, notably downregulating GRAMD1B, IL-6, and G-CSF. Its activity can be modulated by synthetic mimics or antisense inhibitors, both of which are explored as experimental therapeutics. High expression of miR-4646-5p is associated with better clinical outcomes in TNBC, suggesting utility as a prognostic biomarker. The broad regulatory effects on gene networks position miR-4646-5p as a promising target for cancer therapy, though challenges remain in precision delivery and safety assessment[1]. If more structured disease or drug interaction data are needed, database queries (such as miRBase, or cancer miRNA atlases) are recommended, but published evidence supports miR-4646-5p primarily in preclinical models as a tumor suppressor and a molecular biomarker for breast and possibly other cancers[1].

Other names

mir-4646hsa-mir-4646MIR4646miR-4646-5p

miRNA mimics: Restore or enhance miR-4646-5p function (reducing cell growth, proliferation, and migration). miRNA inhibitors (e.g., LNA antisense): Block or sequester endogenous miR-4646-5p, reducing its effects on target gene expression (e.g., GRAMD1B).